Latest Wearables News

Nanoveu’s subsidiary EMASS has partnered with Arrow Electronics to accelerate the deployment of its ultra-low-power ECS-DoT edge AI chip, aiming to simplify always-on AI integration across multiple industries.

dorsaVi reports breakthrough RRAM sensor performance and secures a major US physical therapy deal, backed by a $5 million capital raise and new leadership appointments.

BrainChip Holdings has moved its AKD1500 neuromorphic AI chip into volume production, supported by key supply agreements and expanded distribution channels, while maintaining a stable cash position.

Control Bionics has successfully raised $0.6 million through a shortfall placement, reinforcing investor confidence as it accelerates commercialisation of its neurotechnology in assistive communication and emerging sports markets.

BrainChip Holdings Ltd showcased its leadership in ultra-low-power edge AI technology, emphasizing strong partnerships and a growing product portfolio targeting high-growth sectors like defense and healthcare.

BrainChip Holdings has initiated tape-out for its AKD1500 neuromorphic AI chip, targeting volume production by late Q3 2026 to meet rising demand for ultra-low-power edge AI solutions.

Nanoveu Limited showcased its cutting-edge EMASS semiconductor technology at the Ignite Investment Summit in Hong Kong, highlighting a new ultra-low-power AI chip designed to revolutionize edge computing across multiple industries.

dorsaVi has confirmed its RRAM Reflex Platform achieves biological-grade reflexes with sub-microsecond latency and ultra-low energy use, outperforming leading digital edge AI systems by orders of magnitude.

dorsaVi has achieved a major engineering milestone by validating its RRAM-powered Reflex Platform, delivering neural reflex decisions in under one microsecond with ultra-low energy consumption. This breakthrough paves the way for next-generation robotics, prosthetics, and wearable devices that require rapid, energy-efficient reflex actions.

Advanced Health Intelligence has appointed Dylan Garnett as its new CEO, signaling a strategic pivot towards commercialisation and revenue growth. Garnett’s extensive background in healthcare, insurance, and digital health positions AHI for its next growth phase.

Alterity Therapeutics has unveiled encouraging Phase 2 trial results for ATH434, demonstrating its potential to slow disease progression in Multiple System Atrophy while maintaining a strong safety profile.

Spacetalk Ltd has raised $4.05 million through a combination of a conditional placement and convertible notes to accelerate its geographic expansion and app development, alongside appointing a seasoned director to its board.